Article
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jul 2006
Toffoli Giuseppe, Cecchin Erika, Corona Giuseppe, Russo Antonio, Buonadonna Angela, D'Andrea Mario, Pasetto Lara Maria, Pessa Sergio, Errante Domenico, De Pangher Vincenzo, Giusto Mauro, Medici Michele, Gaion Fernando, Sandri Paolo, Galligioni Enzo, Bonura Salvatore, Boccalon Massimo, Biason Paola, Frustaci Sergio
Abstract excerpt
PURPOSE: UGT1A1*28 polymorphism has been associated with decreased glucuronidation of SN38, the active metabolite of irinotecan. This could increase toxicity with this agent. PATIENTS AND METHODS: In a prospective study, 250 metastatic colorectal cancer patients were treated with irinotecan, fluo...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
